NewAmsterdam Pharma Co. NV (NAMS)
22.50
+0.24
(+1.06%)
USD |
NASDAQ |
Oct 07, 13:26
NewAmsterdam Pharma Enterprise Value : 1.985B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 1.985B |
| October 05, 2026 | 2.047B |
| October 02, 2026 | 2.094B |
| October 01, 2026 | 2.207B |
| September 30, 2026 | 2.226B |
| September 29, 2026 | 2.166B |
| September 28, 2026 | 2.139B |
| September 25, 2026 | 2.021B |
| September 24, 2026 | 2.040B |
| September 23, 2026 | 2.033B |
| September 22, 2026 | 2.109B |
| September 21, 2026 | 2.021B |
| September 18, 2026 | 2.011B |
| September 17, 2026 | 1.945B |
| September 16, 2026 | 1.857B |
| September 15, 2026 | 1.854B |
| September 14, 2026 | 1.996B |
| September 11, 2026 | 2.047B |
| September 10, 2026 | 1.937B |
| September 09, 2026 | 2.046B |
| September 08, 2026 | 2.380B |
| September 04, 2026 | 2.353B |
| September 03, 2026 | 2.406B |
| September 02, 2026 | 2.376B |
| September 01, 2026 | 2.297B |
| Date | Value |
|---|---|
| August 31, 2026 | 2.346B |
| August 28, 2026 | 2.412B |
| August 27, 2026 | 2.517B |
| August 26, 2026 | 2.589B |
| August 25, 2026 | 2.581B |
| August 24, 2026 | 2.524B |
| August 21, 2026 | 2.644B |
| August 20, 2026 | 2.633B |
| August 19, 2026 | 2.721B |
| August 18, 2026 | 2.571B |
| August 17, 2026 | 2.530B |
| August 14, 2026 | 2.539B |
| August 13, 2026 | 2.503B |
| August 12, 2026 | 2.639B |
| August 11, 2026 | 2.614B |
| August 10, 2026 | 2.657B |
| August 07, 2026 | 2.654B |
| August 06, 2026 | 2.620B |
| August 05, 2026 | 2.591B |
| August 04, 2026 | 2.606B |
| August 03, 2026 | 2.599B |
| July 31, 2026 | 2.634B |
| July 30, 2026 | 2.713B |
| July 29, 2026 | 2.649B |
| July 28, 2026 | 2.657B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProQR Therapeutics NV | 114.03M |
| Pharming Group NV | 653.60M |
| argenx SE | 57.52B |
| Ionis Pharmaceuticals, Inc. | 7.422B |
| Arcutis Biotherapeutics, Inc. | 2.879B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.14M |
| Revenue (Quarterly) | 3.701M |
| Total Expenses (Quarterly) | 67.84M |
| EPS Diluted (Quarterly) | -0.5199 |
| Gross Profit Margin (Quarterly) | 98.41% |
| Profit Margin (Quarterly) | -1.73K% |
| Earnings Yield | -9.68% |
| Normalized Earnings Yield | -8.675 |